Surveillance strategies for the detection of new SARS-CoV-2 variants across epidemiological contexts

Kirstin I. Oliveira Roster¹, Stephen M. Kissler¹, Enoma Omoregie², Jade C. Wang², Helly Amin², Steve Di Lonardo², Scott Hughes ^{†2}, Yonatan H. Grad ^{*†1}

¹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA

² New York City Department of Health and Mental Hygiene, New York City, NY

[†] Co-senior authors

* Correspondence: ygrad@hsph.harvard.edu

Abstract

1

2 3

4

5 6

7

8

9 10

11

16

17 Rapid identification of new SARS-CoV-2 variants is a critical component of the public health 18 response to the COVID-19 pandemic. However, we lack a quantitative framework to assess 19 20 the expected performance of sampling strategies in varying epidemic contexts. To address this gap, we used a multi-patch stochastic model of SARS-CoV-2 spread in New York City to 21 22 evaluate the impact of the volume of testing and sequencing, geographic representativeness of sampling, location and timing of variant emergence, and relative variant transmissibility on 23 the time to first detection of a new variant. The strategy of targeted sampling of likely emer-24 gence locations offered the most improvement in detection speed. Increasing sequencing ca-25 pacity reduced detection time more than increasing testing volumes. The relative transmissi-26 bility of the new variant and the epidemic context of variant emergence also influenced detec-27 28 tion times, showing that individual surveillance strategies can result in a wide range of detection outcomes, depending on the underlying dynamics of the circulating variants. These find-29 ings help contextualize the design, interpretation, and trade-offs of genomic surveillance strat-30

31 egies.

32 Introduction

33

Genomic surveillance is an important tool for public health response to infectious disease (1,2). For pathogens such as SARS-CoV-2, genomic surveillance has enabled rapid identification and characterization of genetic variants that differ in transmissibility, virulence, and antigenic space, and thus informed disease control policies and the design and clinical use of therapeutics and vaccines (3–7).

39

40 Many questions remain about the impact of sampling strategies on the time to first detection of a variant. Guidelines suggest specific sequencing rates or fixed sequencing volumes (7)(8). 41 depending on available resources, logistical considerations, overall SARS-CoV-2 prevalence, 42 and surveillance objectives. They also emphasize the importance of sequencing cases that 43 accurately reflect all SARS-CoV-2 infections, which requires representativeness of both test-44 ing and sequencing. In low- and middle-income countries, increasing testing volume as a way 45 of improving the representativeness of sampling is most important to reducing variant detec-46 tion times (9). However, we lack a general quantitative assessment of sampling strategies to 47 48 detect new variants—where 'new' refers to local emergence of a novel variant or the importation of an emerging, known or an unknown variant—within a target detection time that consid-49 ers the role of geographic representativeness of sampling, the optimal testing and sequencing 50 volumes, and epidemic context. 51

52

To address this gap, we simulated the impact of a set of surveillance strategies on variant 53 detection across a range of contexts. We developed a multi-patch stochastic transmission 54 model for SARS-CoV-2 in New York City (NYC) and incorporated empirical human mobility 55 56 data for the geographic dispersal of pathogens. We chose NYC as a case study given its experience with genomic surveillance and publicly available data on testing, sequencing, and 57 mobility (10,11). We simulated the introduction of new variants with varying levels of transmis-58 sibility in locations across the city and at multiple introduction times relative to the introduction 59 of the previously dominant variant. We then simulated testing and sequencing scenarios, var-60 61 ying both the volume and distribution of sampling, and computed the time to first detection, the overall burden of disease, and the geographic variability of the disease burden under each 62 strategy. By developing this framework, we aimed to contextualize decision-making on ge-63 nomic surveillance within the diversity of possible disease scenarios. 64

66 67 **Metho**

65

69

67 Methods68

Data.

70 Baseline COVID-19 testing rates (609 tests per 100,000 residents per week) and sequencing 71 rates for NYC were obtained from the NYC Department of Health and Mental Hygiene (NYC 72 DOHMH) (11) from December 2020 until November 2021 at the geographic resolution of mod-73 74 ified ZIP-code tabulation areas (MODZCTAs). Mobility data were obtained from Meta via the Facebook Data for Good Initiative (12), which reported the physical locations of anonymized 75 app users within 600m-by-600m tiles in 8-hour intervals. These data were aggregated to both 76 77 MODZCTAs and boroughs and used to construct a mixing matrix estimating the rate of inter-78 personal encounters among the residents of NYC. We used data from the United States Census Bureau to define mappings between MODZCTAs, tiles, and boroughs. The main analysis 79 was conducted at the geographic scale of boroughs. We conducted a sensitivity analysis at 80 the level of MODZCTAs. Full details are provided in the Supplementary Materials and Meth-81 ods. 82 83

84 Model structure.

To simulate the introduction and subsequent transmission of a novel SARS-CoV-2 variant, we 86 constructed a multi-patch, two-variant stochastic compartmental model that builds on the basic 87 structure of a Susceptible-Exposed-Infectious-Recovered-Susceptible (SEIRS) model. A first 88 variant was seeded in the population and a single index case of a novel variant was introduced 89 at varying times and in varying locations. The new variant was simulated to be more infectious 90 than the previously circulating variant. In sensitivity analyses (see Supplemental Material), we 91 considered variants that also had greater and faster immune evasion. Individuals progressed 92 stochastically through the states defined by variant characteristics (cross-protection, transmis-93 94 sion probability, duration of latent and infectious periods) and the number of individuals in each compartment. The probability of transmission between geographic locations (patches repre-95 senting a borough or MODZCTA) was governed by the contact between boroughs (as ob-96 served through human mobility), and the relative quantities of infectious and susceptible resi-97 dents. We accounted for imperfect test sensitivity and specificity and for infection-induced be-98 havioral changes, such as reducing contacts in response to a positive test. We then assessed 99 the impact on detection outcomes of different characteristics of the surveillance strategy and 100 the epidemiological context, specifically the volume of testing and sequencing, the geographic 101 102 distribution of testing, the introduction time and location of the second variant relative to the first, the probability of transmission, and the connectivity (inward and outward mobility) of in-103 troduction and sampling locations. Full details on the model structure are provided in the Sup-104 plementary Materials and Methods. Code is available at github.com/gradlab/detecting-105 sarscov2-variants. 106

107108 Statistical analysis.

109

110 The main outcomes in this study were the time to variant detection (the number of days between when the index case becomes infectious and laboratory confirmation of the new variant 111 among sequenced specimens), the cumulative number of infections, and the variation in cu-112 mulative infections across locations. We ran 100 simulations per scenario and calculated the 113 arithmetic means, medians, and confidence intervals of the main outcomes across simula-114 115 tions. For sampling schemes, we considered (1) the distribution of test volume in New York City provided to DOHMH, which we termed 'baseline' testing, (2) test volumes distributed by 116 population density, and (3) test volumes distributed randomly across locations. We also con-117 sidered "focused testing scenarios" in which 20-100% of tests were allocated in a single loca-118 tion, with the remaining tests distributed evenly among the other locations according to their 119 population size. For total testing volumes, we considered a range between 5% and 300% of 120 the reported testing volume. For sequencing rates, we considered a range between 1% and 121 90% of all positive tests to be selected for sequencing. In a sensitivity analysis, we evaluated 122 123 fixed sequencing quantities instead of sequencing proportions, which distinguished the marginal contribution of sequencing versus testing alone. 124 125

When all introduction times produced qualitatively similar results, we reported in the main text the results from the scenario in which the new variant is introduced just before the outbreak peak of the previously dominating variant (at t = 50 days). In this scenario, detection was expected to be at or near its slowest, due to high background prevalence and depletion of susceptible individuals. Full results for all parameter combinations are provided in the **Supplementary Data**.

134 **Results**

135

137

136 Geographic sampling strategy

Relative to the baseline volume and 138 distribution of testing and sequenc-139 ing in NYC (the "baseline" testing 140 and sequencing strategy), detection 141 142 times were similarly distributed when test volumes were allocated 143 to be (a) proportional to the popula-144 tion density or (b) uniformly at ran-145 dom across locations (Fig. 1). This 146 similarity across geographic sam-147 pling strategies was unaffected by 148 the outcome measure used as well 149 as the timing and location of the 150 new variant's introduction. How-151 ever, the geographic sampling 152 strategy affected detection out-153 comes if the introduction location of 154 the new variant was oversampled. 155 Allocating a greater proportion of 156 tests in a single location reduced 157 detection times and cumulative in-158 fections of variants emerging in that 159



Figure 1. Distribution of detection times by geographic sampling strategy. Points depict the time between variant introduction and detection in days for the scenarios where tests are sampled geographically according to the baseline testing strategy, proportionally to population size, or randomly across New York City (at variant introduction 50 days after the prior variant, 30% of baseline test volume, and 10% sequencing rate). Boxes and whiskers depict the minimum, lower 25%, median, upper 75%, and maximum detection times.

location but increased detection times of variants that first appeared elsewhere (Fig. 2). This effect was especially pronounced in Staten Island and Brooklyn, but weaker in Manhattan

- 162 (Supplementary Fig. S5).
- 163



Figure 2. Detection time by proportion of tests allocated in a single location. Lines depict the average detection time for scenarios where between 20% and 100% of tests are sampled from a single location, and the remaining tests are evenly distributed across the remaining locations by population size. The lines distinguish between scenarios where the variant emerged in the primary allocation location, i.e., test over-sampling and emergence occurred in the same location (blue), and scenarios where the variant emerged in one of the other locations, i.e., test over-sampling and emergence occurred in different locations (red). Ribbons depict the 95% confidence interval for the detection time.

164

165 **Testing and sequencing volumes**

166

6 7 Outcomes varied considerably across testing and sequence

Outcomes varied considerably across testing and sequencing rates, with higher rates leading to faster detection, fewer cases, and less variation in cumulative infections across locations (**Fig. 3**). In accordance with sampling guidelines for well-resourced settings (7), we assumed

that a fixed percentage of tests was sequenced. Thus, increasing the number of tests alsoincreased the number of sequenced samples.

172

177

To better understand the individual contributions of testing and sequencing, we fixed the quantities of samples selected for sequencing at varying testing volumes. Fixed sequencing volumes were implemented as a cap on the maximum number of samples that can be sequenced per day. The actual number of sequenced cases depended on the test positivity rate.

The improvement in variant detection with increasing test volumes at a given sequencing proportion was driven by the increase in sequencing volume rather than test volume. At all levels of testing, increasing the number of sequenced samples reduced the detection time, while increasing testing alone had little impact on new variant detection (**Fig. 4**).



Figure 3. Detection outcomes by test quantity and sequencing rate. Lines depict the mean duration between variant introduction and detection in days (A) and the cumulative infections upon detection (B) as a function of daily testing volume (given new variant introduction 50 days after the prior variant, baseline test strategy). Ribbons depict the 95% confidence interval for the detection time. Colors represent proportions of tests selected for sequencing.

182

183 We also considered an alternative interpretation of the sequencing cap, where the sequencing

volume depended on both the test volume and the positivity rate (**Supplement 3**; **Supplementary Materials and Methods**). The results from this sensitivity analysis fall between the fixed volume and fixed rate analyses (**Figs. 3 and 4**). Raising testing capacity improved detection times for low levels of testing (up to 50-75 tests per 100k persons). At higher levels of testing, improvements in detection time were driven primarily by increased sequencing capacity (**Supplementary Fig. 3**).



Figure 4. Detection time by test volume and fixed sequencing capacity. Lines depict the mean duration between variant introduction and detection in days as a function of daily testing volume, colored by the maximum sequencing volume (A), and as a function of daily maximum sequencing volume, colored by the test volume (B) (at variant introduction 50 days after the prior variant and baseline sampling strategy).

Emergence context

193 194 195

We compared introduction times of the new variant as an approximation for varying background prevalence of the previously circulating variant and the population susceptibility to infection.

199

When the second, more 200 201 transmissible variant was introduced into a fully suscep-202 population together 203 tible with the first variant (at t =204 0), the second variant was 205 206 more likely to dominate due to its increased transmissi-207 bility. Under this scenario, 208 the extinction probability of 209 the second variant (defined 210 as the likelihood that a vari-211 ant will cause no more than 212 10 infections) was only 9.6% 213 under the baseline sampling 214 strategy. Both variants gen-215 erally persisted through the 216 duration of the simulation, 217 though the second variant 218 caused more infections. 219 Consequently, at a *t*=0 intro-220 duction time, the second 221 variant was detected in un-222 der 33 days in 95% of simu-223



Figure 5. Detection time of a novel variant across introduction times. Points depict the time between variant introduction and detection in days for different introduction times (with baseline distribution of tests, 30% of baseline test quantity, and sequencing rate 10%). Points are jittered horizontally to help visualize the distribution. Boxes and whiskers depict the minimum, lower 25%, median, upper 75%, and maximum detection times. The extinction probability for each scenario is depicted using inset squares, where the relative area of the red square is proportional to the extinction probability.

lations. If the second variant was introduced after the peak of the first variant's outbreak (at t = 80 or t = 100), the second variant had a high probability of extinction (64.6 and 84.2%, respectively), and if it persisted, it was detected later (at least 56 and 37 days after introduction

in 95% of simulations, respectively). The greatest range of disease dynamics and consequently detection times was observed when the second variant was introduced just before the peak of the first variant (at t = 50), with detection times ranging from 16 to 145 days (**Fig 5**).

The introduction location did not significantly impact the detection time or cumulative disease burden across the city but did influence where infections occurred .The number of infections was highest in locations with the highest mobility connectivity to the emergence location, which was either the introduction location itself or other locations, depending on the mobility matrix. Emergence in Staten Island, for example, produced infections primarily within Staten Island, while emergence in Manhattan led to a high number of infections in Brooklyn and Queens (**Supplementary Fig. S4**).

238 239

230

240 Variant characteristics

We compared variants with different levels of transmissibility, varying the probability of infection given an infectious contact from $\beta = 0.21$ to $\beta = 0.5$ (contrasting with the transmissibility of the first variant of $\beta = 0.2$). This transmission parameter affected the disease dynamics, with more transmissible variants spreading more quickly, leading to earlier detection. All transmission rates yielded a wide range of cumulative infections at detection time (**Fig. 6**).



Figure 6. Detection time by cumulative infections for different transmission rates. Points depict the mean detection time and cumulative number of inupon fections detection, averaged across 100 simulations of each introduction location. for each of the six transmission probabilities, represented by different colors (at variant introduction 50 days after the prior variant, baseline distribution of tests, 30% of baseline test quantity, and sequencing rate 10%). The baseline transmission rate of the pre-existing variant is $\beta = 0.2$.

247

248

249

250 **Discussion**

251

This study provides an assessment of testing and sequencing strategies for the detection of new SARS-CoV-2 variants to help inform genomic surveillance policies. We considered varying quantities and distributions of resources within a wide range of potential settings for variant emergence and assessed how they influenced variant detection times and the undetected disease burden.

257

Our results confirm that variant detection is governed by both the surveillance strategy and the epidemic dynamics in which the new variant arises (13). The relative transmissibility of the new variant as well as the context of variant emergence influenced its speed of spread and extinction probability, which in turn affected detection outcomes (Figs. 5 and 6).

262

Surveillance guidelines stipulate the need for representative sampling strategies, which re-263 quire not only that a random subset of positive cases be chosen for sequencing, but that pos-264 itive cases also accurately reflect infections across the population; non-representative sam-265 pling delays the detection of new variants (14). Nonrepresentative testing and sequencing 266 must be considered separately and jointly, along dimensions such as demography, socioeco-267 nomic factors, disease outcome, and geography. In this study, we assessed the role of geog-268 raphy in representative sampling. For variation in the geographic distribution of sequencing, 269 270 other work found that if sampling was not representative, then raising test volume improved variant detection times more than raising sequencing rates (9). Our study considered the ge-271 ographic distribution of testing, as well as the volume of both testing and sequencing, and 272 found that in the context of random sampling of tests for sequencing, improvements in detec-273 tion time were driven primarily by increases in sequencing volume rather than testing volume 274 (Fig. 4). The geographic distribution of residents receiving tests impacted detection outcomes 275 276 only via the proximity to the emergence location of the new variant (Fig. 2), though careful test distribution matters to many related public health and social equity objectives (14-16). Over-277 sampling emergence locations improved detection outcomes, underscoring the importance of 278 targeted sequencing, for example at ports of entry or of patients with prolonged viral replication 279 (8). The connectivity of the introduction location did not impact detection times but did affect 280 where infections occurred before variant detection (Supplement 3). Variants that emerged 281 among residents of boroughs with more inward and outward mobility produced more infections 282 283 in other boroughs. In our simulations, a variant first appearing in a resident of Manhattan, for example, caused more infections on average in Brooklyn and Queens than in Manhattan itself. 284 Failing to adequately sample locations near emergence or those highly connected to emer-285 gence locations will lead to a disproportionate number of infections in those locations. 286

287

The number of undetected infections varied widely for a given transmission rate, even at fixed detection times (**Fig 6**). This result demonstrated the challenge of understanding the epidemiologic scenario on discovery of a new variant and the need for combining pathogen genome sequencing with other forms of surveillance. More work is also needed to understand whether optimal surveillance strategies differ if the primary objective is monitoring or detecting variants and how to position genomic surveillance within the broader landscape of sometimes competing public health objectives.

The model in this study was designed to be simple, while accounting for the most important 296 factors affecting testing and sequencing, and to help attain a gualitative understanding of 297 which parameters influence detection times and undetected infections. Consequently, the sim-298 299 ulation results, such as the detection times, should not be interpreted as predictions. Specific simplifications include the modeling of single introductions of a novel variant, rather than ac-300 counting for multiple introductions or several variants. We also assumed homogeneous mixing 301 within locations and did not account for age structure, social networks, or social determinants 302 of health. SARS-CoV-2 infection risk varies across socioeconomic and demographic groups. 303 due in part to variability in the average number of contacts, vaccine uptake, long- and short-304 distance mobility, comorbidities linked to more severe disease outcomes, and other social 305 factors (17–19). While we incorporated neighborhood-level variations in movement, we did 306 not include within-neighborhood heterogeneity or between-neighborhood variation in social 307 determinants of health. A basic first analysis suggests that household income correlates neg-308 atively with undetected infections in our simulations (Supplement 4). Future work may explore 309 how these heterogeneities influence emergence locations of new variants, disease dynamics, 310 and consequently detection outcomes. 311

312

The model in this study also took a simplified perspective of genomic surveillance processes.

We assumed random sampling of positive tests and did not account for variations in specimen quality across testing sites or in access to testing, which may cloud estimates of the prevalence of circulating variants (20). In this sense, our model takes an idealized view of our capacity to sample randomly from the population in each borough or zip code.

Even though we incorporated human mobility data, the model did not account for human responses to the epidemiological situation, such as reduced contact rates during periods of high or rising prevalence, or changes in public health policies like mask mandates. Contact patterns vary over time, not just across places, and future studies should examine how new variant detection changes when incorporating time-varying human behavior.

Detection of novel variants remains a critical component of the response to the COVID-19 325 pandemic. Emerging empirical evidence on genomic surveillance of SARS-CoV-2 variants has 326 allowed public health agencies to provide guidance on sampling strategies to detect and mon-327 328 itor variants, though more research is needed to anticipate the impact of these strategies under as yet unseen epidemiologic settings. This modeling study aimed to contribute to these ongo-329 330 ing efforts to assess variant detection strategies, by simulating detection outcomes for varying testing and sequencing rates in NYC. We focused on the role of geography in representative 331 sampling as well as the context of variant emergence. The epidemiologic context, including 332 emergence timing and background prevalence, played an important role in shaping detection 333 times and undetected disease burdens. Targeted sampling of emergence locations was the 334 primary aspect of geographical representativeness examined in our model that improved de-335 tection outcomes. Increased testing is an important tool to enable more representative sam-336 pling (9), though in well-resourced settings with random sampling, as was assumed in this 337 case study of NYC, increasing sequencing capacity rather than testing had a larger impact on 338 improving detection speeds. 339

340

324

341 342

343 Acknowledgments

The authors thank Faten Takai for helpful feedback on the manuscript and the Public Health Lab whole genome sequencing and data units.

346

347 Funding

K. Oliveira Roster gratefully acknowledges the support of the São Paulo Research Foundation
 (FAPESP) under grant 2021/11608-6. This project has been funded by contract 200-2016 91779 and 6NU50CK000517-01-07 with the Centers for Disease Control and Prevention. Dis claimer: The findings, conclusions, and views expressed are those of the author(s) and do not
 necessarily represent the official position of the Centers for Disease Control and Prevention
 (CDC).

354

356 Supplementary Materials and Methods

357 358 **Data**

359

361

360 *Mobility*

Through its Facebook Data for Good initiative, Meta provides aggregated and anonymized 362 movement data from users who have enabled location sharing (12). It is available in 8-hour 363 364 intervals and with a maximum geographic resolution of 600-by-600m tile sizes. We leveraged this data to compute the average share of users moving between geographic tiles on a given 365 day, aggregated to both modified zip code areas (MODZCTA) and boroughs. This percentage 366 was rescaled to the population size of each location, under the assumption that Facebook 367 users who activate location sharing are representative of NYC residents, which may not be 368 true in practice and may limit our ability to accurately capture human movement across the 369 city. The movements were captured in the raw mobility matrix M, where an entry $M_{\{i-i\}}$ indi-370 cates the number of movements from location i to location j. We then computed a contact 371 matrix from the mobility matrix under the assumption of homogeneous mixing. The probability 372 that a resident of location i has contact with a resident of location j in any location k was 373 defined as: 374

$$k_{\{i,j\}} = \sum_{k} \frac{M_{\{i-k\}}M_{\{j-k\}}\mu_{contacts}}{\sum_{l} M_{\{l-k\}}}$$

Where $\mu_{contacts}$ is the average number of contacts per person, $M_{\{i->k\}}$ is the number of individuals moving from location *i* to location *k*, and $\sum_{l} M_{\{l->k\}}$ is the sum of all individuals moving to location *k*. This contact matrix determined the coupling strength of two locations in the mathematical model, and therefore influenced the likelihood for an infection to spread between the two locations.

382 Testing and Sequencing Rates

Weekly COVID-19 testing rates and sequencing rates by MODZCTA are published by the NYC Department of Health and Mental Hygiene (16). The baseline test rate was calculated as the daily average from December 2020 to November 2021.

387 388

390

381

389 Compartmental Model Structure

We implemented a multi-patch, two-variant stochastic compartmental model which builds upon the basic structure of an SEIRS model. Exposure, testing, sequencing, isolation, recovery, waning (cross-)protection, and reinfection were treated as stochastic events. The model explicitly incorporated human mobility, testing and sequencing rates, as well as test sensitivity and specificity. It also included control measures to account for the fact that testing strategies may impact disease dynamics if infectious individuals reduce their contacts upon receiving a positive test result.

398

The model structure is presented in Supplemental Figure 1 and described in more detail be-399 low. The corresponding parameters are listed in Supplemental Table 1. Susceptible (S) indi-400 viduals may be exposed (E) to one of two variants, represented by subscripts 1 and 2, or they 401 may isolate if they receive a false positive test result (S_q) . After a latent period, an exposed 402 individual moves to one of five infectious compartments depending on their reporting and iso-403 lation outcome: an infection may be unreported (I_{II}) , for example if it is asymptomatic or de-404 tected only via an at-home test. A positive case may be detected at an official test center (I_T) , 405 leading the person to isolate (I_{Tq}) or not (I_{Tnq}) . Finally, the positive test may also be sequenced 406 (I_G) , again separating individuals by their isolation status (I_{Gq}, I_{Gnq}) . After recovery, individuals 407

have temporary full protection against reinfection with either variant while they remain in compartments R_U, R_T, R_G . Full protection wanes over time at variant-specific rates, making individuals susceptible to reinfection with one $(S_{1\{1\}}, S_{2\{1\}}, S_{1\{2\}}, S_{2\{2\}})$ or both variants $(S_{12\{1\}}, S_{12\{2\}})$. The model incorporates a variant-specific leaky immunity parameter $(a_{11}, a_{12}, a_{21}, a_{22})$, which defines the reduction in the probability of reinfection after full protection has waned.

- 413
- 414





415 416 417 418 $\frac{dS}{dt} = \epsilon S_q - p_t (1 - p_{TP}) p_q S - b_1 k I_1 S - b_2 k I_2 S$ 419 $\frac{dS_q}{dt} = p_t (1 - p_{TP}) p_q S - \epsilon S_q$ 420 421 Variant 1:

$$\begin{array}{ll} \begin{array}{l} & \frac{dE_1}{dt} = b_1 k l_1 S + a_{1(1)} b_1 k l_1 (S_{1(1)} + S_{12(1)}) + a_{1(2)} b_1 k l_1 (S_{1(2)} + S_{12(2)}) - \frac{1}{L_1} E_1 \\ \hline \\ \begin{array}{l} & \frac{dI_{21}}{dt} = \frac{1}{L_1} E_1 \left[l_1 (-p_t) + p_t p_{FN} \right] - \frac{1}{D_1} I_{01} \\ \hline \\ & \frac{dI_{7n}}{dt} = \frac{1}{L_1} E_1 \left[p_t (1 - p_g) p_{TP} p_g \right] - \frac{1}{D_1} I_{7n} \\ \hline \\ \begin{array}{l} & \frac{dI_{7n}}{dt} = \frac{1}{L_1} E_1 \left[p_t (1 - p_g) p_{TP} p_g \right] - \frac{1}{D_1} I_{0n} \\ \hline \\ & \frac{dI_{7n}}{dt} = \frac{1}{L_1} E_1 \left[p_t (1 - p_g) p_{TP} (1 - p_g) \right] - \frac{1}{D_1} I_{7ng} \\ \hline \\ & \frac{dI_{6n}}{dt} = \frac{1}{L_1} E_1 \left[p_t p_g p_{TP} p_g \right] - \frac{1}{D_1} I_{6n} \\ \hline \\ & \frac{dI_{6n}}{dt} = \frac{1}{L_1} E_1 \left[p_t p_g p_{TP} (1 - p_g) \right] - \frac{1}{D_1} I_{6ng} \\ \hline \\ & \frac{dR_{7n}}{dt} = \frac{1}{D_1} \left[(I_{7n} + I_{7ng}) - R_{71} (w_{1(1)} + w_{2(1)} - w_{1(1)} w_{2(1)}) \\ \hline \\ & \frac{dR_{7n}}{dt} = \frac{1}{D_1} \left((I_{7n} + I_{6ng}) - R_{61} (w_{1(1)} + w_{2(1)} - w_{1(1)} w_{2(1)}) \\ \hline \\ & \frac{dS_{12(1)}}{dt} = w_{1(1)} (1 - w_{2(1)}) (R_{01} + R_{71} + R_{61}) - a_{1(1)} b_1 k l_1 S_{12(1)} - a_{2(1)} b_2 k l_2 S_{12(1)} \\ \hline \\ & \frac{dS_{12(1)}}{dt} = w_{1(1)} w_{2(1)} (R_{01} + R_{71} + R_{61}) - a_{2(1)} b_2 k l_2 S_{2(1)} \\ \hline \\ & \frac{dS_{12(1)}}{dt} = w_{2(1)} (1 - w_{1(1)}) (R_{01} + R_{71} + R_{61}) - a_{2(1)} b_2 k l_2 S_{2(1)} \\ \hline \\ & \frac{dS_{12(1)}}{dt} = w_{2(1)} (1 - w_{1(1)}) (R_{01} + R_{71} + R_{61}) - a_{2(1)} b_2 k l_2 S_{2(1)} \\ \hline \\ & \frac{dS_{12}}{dt} = b_2 k l_2 S + a_{2(1)} b_2 k l_2 (S_{2(1)} + S_{12(1)}) + a_{2(2)} b_2 k l_2 (S_{2(2)} + S_{12(2)}) - \frac{1}{L_2} E_2 \\ \hline \\ & \frac{dU_{7n}}{dt} = \frac{1}{L_2} E_2 \left[p_t (1 - p_g) p_{TP} p_g \right] - \frac{1}{D_2} I_{7n} \\ \hline \\ & \frac{dI_{7n}}{dt} = \frac{1}{L_2} E_2 \left[p_t (1 - p_g) p_{TP} p_g \right] - \frac{1}{D_2} I_{7n} \\ \hline \\ & \frac{dI_{7n}}{dt} = \frac{1}{L_2} E_2 \left[p_t p_g p_{TP} p_g \right] - \frac{1}{D_2} I_{6ng} \\ \hline \\ & \frac{dI_{7n}}{dt} = \frac{1}{L_2} E_2 \left[p_t p_g p_{TP} p_g \right] - \frac{1}{D_2} I_{6ng} \\ \hline \\ & \frac{dI_{7n}}{dt} = \frac{1}{L_2} E_2 \left[p_t p_g p_{TP} p_g \right] - \frac{1}{D_2} I_{6ng} \\ \hline \\ & \frac{dI_{7n}}{dt} = \frac{1}{L_2} E_2 \left[p_t p_g p_{TP} p_g \right] - \frac{1}{D_2} I_{6ng} \\ \hline \\ & \frac{dI_{7n}}{dt}$$

450
$$\frac{dS_{2\{2\}}}{dt} = w_{2\{2\}}(1 - w_{1\{2\}})(R_{U2} + R_{T2} + R_{G2}) - a_{2\{2\}}b_2kI_2S_{2\{2\}}$$
451

where
$$I_1 = I_{U1} + I_{Tq1} + I_{Tq1} + I_{Gq1} + I_{Gq1}$$
 and $I_2 = I_{U2} + I_{Tq2} + I_{Tq2} + I_{Gq2} + I_{Gq2}$

Where p_t is the test rate, p_g is the sequencing rate, p_q is the control measure compliance rate, p_{TP} is the true positive rate, $a_{x\{y\}}$ is the leaky immunity parameter, $w_{x\{y\}}$ is the waning full immunity parameter, b is the probability of infection given contact, L is the average duration of the latent period, D is the average duration of the infectious period, k is the contact matrix, and ϵ is the rate of ending control measures if false positive.

460 461 462

459

452

453

Table S1. Parameters

Parameter	Description
p_t	Test rate (share of population)
p_g	Sequencing rate (share of positive tests)
p_q	Control measure compliance rate
p_{TP}	True positive rate of test instrument
$a_{x\{y\}}$	Leaky immunity parameter: percent suscepti- bility to infection with variant x after infection with variant y
$W_{x\{y\}}$	Waning full immunity parameter: rate of loss of immunity against variant x after infection with variant y
b	Probability of infection given a contact with an infectious individual
L	Average duration of latent period
D	Average duration of infectious period
k	Contact matrix
E	Rate of ending control measures with false positive test result

463

464

465 466

467

468 469

Geographic Test Distribution

Simulations

470 471

We implement the following primary strategies for testing allocation. Supplemental Figure 2 shows an example of the test rates under each scenario.

- Baseline: Tests are allocated according to the current NYC strategy, computed as the average allocation and daily test quantity between December 2020 and November 2021.
- Population density-based allocation: The same number of tests are distributed homo geneously across the city, so that each location has the same test rate. Locations with
 a larger population receive more tests than less densely populated boroughs or
 MODZCTAs.
- Random allocation: The available tests are distributed randomly across locations. This effectively results in higher per-capita test rates in less densely populated areas.

484 Test Volume

We varied the quantity of available tests from 5% to 400% of the NYC average of 7,184 tests per day (87 tests per 100,000 persons). Changing the quantity of available tests may be understood as either increased capacity or reduced reporting, for example due to a shift toward home testing. From February 2020 to September 2021, an estimated 75 percent of COVID-19 infections went unreported (21). With the emergence of the Omicron sub-variants BA.2.12 and BA.2.12.1, underreporting may be as high as 95 percent (22).

492

483

To further understand the role of the geographic test distribution, we also considered "focused testing scenarios", where individual locations are over-sampled. In these scenarios, 20-100% of all tests were sampled from a single location and the remaining tests were distributed across the remaining locations proportional to population size. We then compared how detection outcomes differed when the new variant emerged in the over-sampled location *versus* one of the

498 other locations.



Supplemental Figure S2. Sample number of tests per capita at the borough level. Boroughs are colored by the proportion of the population that is tested each week under the baseline (A), density-based (B), and random (C) sampling strategy.

499

- 500
- 501
- 502

503 Sequencing volume

504

509

The main analysis considered sequencing probabilities of 5-90% of all positive tests. The sequencing volume for each day of the simulation was therefore determined by the test volume and the number of infections. Raising test volume for a given epidemiologic scenario effectively raises sequencing volume at fixed sequencing probabilities.

In two sensitivity analyses, we sought to isolate the effect of testing and sequencing volumes
 by placing a cap on sequencing resources:

512 - Sensitivity analysis 1: At any time point, a fixed number of positive tests was 513 sequenced. If there were fewer positive tests than sequencing resources (due to low 514 prevalence), then all positive tests were sequenced. The maximum sequencing

volume was reached when there was a sufficient quantity of positive tests, i.e.,
 sufficiently high prevalence and test volume. The effective sequencing volume did not
 necessarily vary for different sequencing caps, if prevalence and/or test volume were
 low.

Sensitivity analysis 2: A fixed number of tests were assigned as potentials for sequencing, akin to placing a stamp on a subset of test kits. If a test with a stamp was positive, the sample was sequenced. The maximum sequencing volume was achieved when all (stamped) tests were positive, which depended on the number of infections. The effective sequencing volume necessarily varied between the different sequencing caps.

525 526

529

527

528 Variants

530 The first variant was modeled to resemble the Delta SARS-CoV-2 variant with an effective 531 transmission probability of 0.2. We then introduced a second variant, which was (i) more trans-532 missible, (ii) had greater and faster immune evasion, or (iii) both. We considered effective 533 transmission probabilities of 0.21-0.5.

534 535

536 Context of variant emergence

537 We simulated the emergence of the second variant at different locations and different times 538 relative to the introduction of the first variant. The first variant was introduced with a single 539 index case in each location, to simulate even spread across the city. The second variant was 540 541 introduced with one index case in a single location, representing the location of residence of the index case. We simulated all possible introduction locations. Introduction times of the sec-542 ond variant varied from 0 to 150 days after the introduction of the first variant. The introduction 543 544 times represent different contexts, because of varying prevalence of the first variant and varying numbers of susceptible individuals. We did not distinguish between variants that emerged 545 within the city and those that were imported. The index case of the novel variant in our model 546 could thus represent the first case of a newly emerging variant introduced to NYC from outside 547 the city or a globally undetected variant that either emerged within NYC or was imported from 548 outside before detection. 549

550

552

551 Outcome measures

For each simulation, we computed three primary outcome measures. The time to detection 553 was defined as the number of days between the introduction and detection (first sequenced 554 case) of the second variant. Cumulative undetected infections measured the total number of 555 people who were exposed to (i.e., infected by) the second variant in NYC by the time the new 556 variant was detected, including individuals who at detection time were in the latent phase prior 557 to infectiousness, infectious, recovered, or susceptible to reinfection. Finally, we computed the 558 standard deviation of the cumulative undetected infections across locations as an estimate of 559 the geographic variation in disease burden. 560

- 561
- 562
- 563
- 564

565 Supplement 2: Sensitivity analysis of fixed sampling volumes



Supplementary Figure S3. Detection time by fixed volumes of test and sequencing quantities. Lines depict the mean duration between variant introduction and detection in days (A) as a function of daily testing volume, colored by the maximum sequencing volume, and (B) as a function of maximum sequencing volume, colored by the test volume.

566 567

569

568 Supplement 3: Role of introduction location

Intro location: Manhattan Intro location: Staten 70000 8000 60000 50000 nfections 60000 infection 40000 ulative cumulative 40000 30000 m 20000 20000 10000 0 Stater Brooklyr Manhattan Queens Brooklyn Manhattan Bron: Bronz Que

Supplementary Figure S4. Cumulative infections by borough for introduction locations Manhattan and Staten Island. Points depict the number of cumulative infections in each borough at detection time (at variant introduction 50 days after the prior variant, baseline distribution of tests, 30% of baseline test quantity, and sequencing rate 10%). Boxes and whiskers depict the minimum, lower 25%, median, upper 75%, and maximum cumulative infections.



Supplementary Figure S5. Detection time by proportion of tests allocated in single borough introduction location. Lines depict the average detection time for scenarios where between 20% and 100% of tests are sampled from a single location, and the remaining tests are evenly distributed across the remaining locations by population size. The sub-plots distinguish between scenarios where the variant emerged in the primary allocation location, i.e., test over-sampling and emergence occurred in the same location (left), and scenarios where the variant emerged in one of the other locations, i.e., test over-sampling and emergence occurred in different locations (right).

579 580





Supplementary Figure S6. Detection times by introduction location. Points depict the detection time in days
 for each introduction location (at variant introduction 50 days after the prior variant, baseline distribution of tests,
 30% of baseline test quantity, and sequencing rate 10%). Boxes and whiskers depict the minimum, lower 25%,
 median, upper 75%, and maximum detection times.

587

588

589 Supplement 4: Social equity

590

We explored the relationship between socioeconomic variables and the average cumulative undetected exposures at the time of new variant detection across all NYC zip codes (**Supplementary Fig. S7**). We observed a weak negative correlation (Pearson correlation coefficient -0.39), with cumulative exposures decreasing with increasing household income, possibly due to lower population density in wealthier neighborhoods.

596



Supplementary Figure S7. Cumulative undetected exposures by average household income. Points depict the mean cumulative number of infections by household income across 625 simulations (5 simulations for each introduction location) when testing is distributed according to the baseline testing strategy. Colors depict the five boroughs.

597

- 598
- 599
- 600 601

602 **References**

- Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities. JAMA. 2021 Mar 16;325(11):1037–8.
- Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomicinformed pathogen surveillance in Africa: opportunities and challenges. Lancet Infect Dis. 2021 Sep 1;21(9):e281–9.
- Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214
 Demonstrates Superior Antibody Response Against Omicron [Internet]. [cited 2022 Jun
 9]. Available from: https://investors.modernatx.com/news/news-details/2022/Moderna Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214 Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx
- 4. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid
 epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature.
 2022;603(7902):679–86.
- 5. Robishaw JD, Alter SM, Solano JJ, Shih RD, DeMets DL, Maki DG, et al. Genomic
 surveillance to combat COVID-19: challenges and opportunities. Lancet Microbe. 2021
 Sep 1;2(9):e481–4.
- 620 6. Chen Z, Azman AS, Chen X, Zou J, Tian Y, Sun R, et al. Global landscape of SARS-CoV-2 genomic surveillance and data sharing. Nat Genet. 2022 Apr;54(4):499–507.
- 7. WHO. Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August
 2021 [Internet]. World Health Organization; 2021 Aug [cited 2022 Nov 19] p. 21. Available
 from: https://www.who.int/publications-detail-redirect/WHO_2019 nCoV_surveillance_variants
- 8. ECDC. Guidance for representative and targeted genomic SARS-CoV-2 monitoring.
 European Centre for Disease Prevention and Control. 2021 May 3;

- 9. Han AX, Toporowski A, Sacks JA, Perkins MD, Briand S, van Kerkhove M, et al. SARS CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance
 programs. Nat Genet. 2023 Jan;55(1):26–33.
- 10. Vasylyeva TI, Fang CE, Su M, Havens JL, Parker E, Wang JC, et al. Introduction and
 Establishment of SARS-CoV-2 Gamma Variant in New York City in Early 2021 [Internet].
 medRxiv; 2022 [cited 2022 May 29]. p. 2022.04.15.22273909. Available from:
 https://www.medrxiv.org/content/10.1101/2022.04.15.22273909v1
- 11. NYC Coronavirus Disease 2019 (COVID-19) Data [Internet]. NYC Department of
 Health and Mental Hygiene; 2022 [cited 2022 May 25]. Available from:
 https://github.com/nychealth/coronavirus-data
- Maas P. Facebook Disaster Maps: Aggregate Insights for Crisis Response &
 Recovery. In: Proceedings of the 25th ACM SIGKDD International Conference on
 Knowledge Discovery & Data Mining [Internet]. New York, NY, USA: Association for
 Computing Machinery; 2019 [cited 2022 Nov 22]. p. 3173. (KDD '19). Available from:
 https://doi.org/10.1145/3292500.3340412
- Subissi L, von Gottberg A, Thukral L, Worp N, Oude Munnink BB, Rathore S, et al.
 An early warning system for emerging SARS-CoV-2 variants. Nat Med. 2022 May 30;
- Pond EN, Rutkow L, Blauer B, Aliseda Alonso A, Bertran de Lis S, Nuzzo JB.
 Disparities in SARS-CoV-2 Testing for Hispanic/Latino Populations: An Analysis of State Published Demographic Data. J Public Health Manag Pract. 2022 Aug;28(4):330.
- Martin EG. Integrating Health Equity and Efficiency Principles in Distribution
 Systems: Lessons From Mailing COVID-19 Tests. J Public Health Manag Pract.
 2022;28(4):327–9.
- McPhearson T, Grabowski Z, Herreros-Cantis P, Mustafa A, Ortiz L, Kennedy C, et
 al. Pandemic Injustice: Spatial and Social Distributions of COVID-19 in the US Epicenter.
 J Extreme Events. 2020 Dec;07(04):2150007.
- McDonald SA, Devleesschauwer B, Wallinga J. The impact of individual-level
 heterogeneity on estimated infectious disease burden: a simulation study. Popul Health
 Metr. 2016 Dec 1;14:47.
- 18. Rodriguez-Diaz CE, Guilamo-Ramos V, Mena L, Hall E, Honermann B, Crowley JS,
 et al. Risk for COVID-19 infection and death among Latinos in the United States:
 examining heterogeneity in transmission dynamics. Ann Epidemiol. 2020 Dec;52:4653.e2.
- Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk
 factors for severe disease and mortality in COVID-19: A global systematic review and
 meta-analysis. PloS One. 2021;16(3):e0247461.
- Wohl S, Lee EC, DiPrete BL, Lessler J. Sample Size Calculations for Variant
 Surveillance in the Presence of Biological and Systematic Biases. medRxiv. 2022 Jan
 1;2021.12.30.21268453.
- CDC. Cases, Data, and Surveillance [Internet]. Centers for Disease Control and
 Prevention. 2020 [cited 2022 May 26]. Available from:
 https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html

- 670 22. Mandavilli A. Two new Omicron subvariants are spreading quickly in New York State.
- The New York Times [Internet]. 2022 Apr 13 [cited 2022 May 26]; Available from:
- https://www.nytimes.com/live/2022/04/13/world/covid-19-mandates-cases-vaccine

673